Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
April 10, 2025Research and Development Alzheimer's disease, Neurology, TauRx Pharmaceutics, research and development
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the progression of Alzheimer’s disease over …
Infinitopes launches first-in-human trial of vaccine targeting oesophageal cancer
April 9, 2025Research and Development Infinitopes, Oncology, biotech, oesophageal cancer, oncology
The cancer biotech company Infinitopes has gained approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate …
Ipsen’s Iqirvo approved for use in NHS Scotland to treat rare liver disease
April 8, 2025Research and Development R&D, Rare Diseases, Scottish Medicines Consortium, ipsen, primary biliary cholangitis (PBC)
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsen’s Iqirvo (elafibranor) in NHS Scotland for the treatment of …
High Force Research appoints Nathalie Huther as chief commercial officer
April 8, 2025Manufacturing and Production, Research and Development Corporate, High Force Research, cco, manufacturing and production
High Force Research has announced that it has appointed Nathalie Huther as its first chief commercial officer (CCO) following the …
ELRIG appoints Del Trezise as chair
April 8, 2025Research and Development ELRIG, Pharmacy, R&D, drug discovery, non-profit organisation, pharma
ELRIG, a non-profit volunteer-led organisation dedicated to the drug discovery community, has appointed Del Trezise as chair of the board. …
Academy of Medical Sciences invests record £7.6m into early-career biomedical researchers
April 7, 2025Research and Development Academy of Medical Sciences, British Heart Foundation, Corporate, Wellcome, biomedical research, funding
The Academy of Medical Sciences has awarded £7.6m to support 62 early-career biomedical researchers across the UK, marking the largest …
European consortium launches project to advance alpha-emitting radiotherapies
April 7, 2025Research and Development Akiram Therapeutics, European Consortium, Oncology, PreTT, TetraKit Technologies, radiotherapy
A new European research initiative PRE-CISE has been launched with the aim of developing next-generation targeted alpha-therapies for cancer treatment. …
New hormonal treatment launched to help prevent miscarriage in early pregnancy
April 4, 2025Research and Development Besins Healthcare, Reproductive health, hormonal therapy, miscarriage, pregnancy
A new progesterone-based treatment aimed at preventing miscarriage has been launched across the UK, following a major clinical trial that …
Mehiläinen acquires Regina Maria and MediGroup, and welcomes Hellman & Friedman as new shareholder
April 4, 2025Business Services, Marketing Services CVC, Corporate, MediGroup, Mehilainen, Regina Maria, shareholders
Mehiläinen, a Finnish health and social care provider, has announced that it has agreed to acquire Regina Maria and MediGroup. …
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
April 4, 2025Research and Development CHMP, Oncology, bristol myers squibb, immunotherapy, lung cancer, opdivo
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for …
Curium Pharma announces acquisition of Monrol
April 3, 2025Manufacturing and Production, Research and Development Curium Pharma, Monrol, Oncology, acquisition, nuclear medicine, radiopharmaceutical products
Curium Pharma, a nuclear medicine company, has acquired Eczacıbaşı-Monrol Nuclear Products (Monrol), a nuclear medicine player. With facilities across Europe …
Enosium Life Science acquires RWEality
April 3, 2025Business Services, Consultancy Consultancy, Corporate, Enosium Life Sciences, RWEality, acquisition, life sciences, research and development
Enosium Life Science, which specialises in life sciences, has acquired RWEality, a consultancy focused on public policies, technology and healthcare …
Bend Bioscience adds commercial spray drying facility to Georgia site
April 3, 2025Manufacturing Services, Manufacturing and Production Bend Bioscience, CDMO, Devices, manufacturing, pharma
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry granulation system at its facility …
GRI Bio announces two global patents granted for Europe and Japan
April 2, 2025Research and Development Chronic Diseases, GRI Bio, autoimmune diseases, biotech, fibrotic diseases, inflammatory diseases, patent
GRI Bio, a biotech company that specialises in treatment for inflammatory, fibrotic and autoimmune diseases, has announced that two global …
Usama Dar appointed as chief product and technology officer at CluePoints
April 2, 2025Research and Development Pharmacy, clinical trial analysis, cluepoints, pharma, research and development
CluePoints has appointed Usama Dar as its new chief product and technology officer, effective 1 April 2025. This follows Dar’s …
Dupixent approved as first biologic medicine in Japan for COPD patients
April 2, 2025Research and Development COPD, Chronic Diseases, Regeneron, Sanofi, biotech, respiratory disease
The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment …
ADHD coach and breathwork experts to run workshop for ADHD management
April 2, 2025Design & Creative, Freelancers ADHD, Neurology, healthcare, mental health, nervous system
ADHD coach John Harrington and breathwork facilitator Martin O’Toole will collaborate on ‘Breathwork for ADHD and Beyond’, a breathwork-orientated session …
Rybelsus found to reduce major adverse cardiovascular events in Novo Nordisk trial
April 1, 2025Research and Development Cardiology, Novo Nordisk, cardiometabolic diseases, research and development
Novo Nordisk announced results from its SOUL cardiovascular outcomes trial. Rybelsus (oral semaglutide) significantly reduced the risk of major adverse …
Corcept’s relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint
April 1, 2025Research and Development Corcept Therapeutics, Oncology, ovarian cancer, research and development
Corcept Therapeutics announced that relacorilant plus nab-paclitaxel met its primary endpoint of improved progression-free survival in ROSELLA, the company’s phase …
Secarna Pharmaceuticals to announce positive new data at cancer research conference
April 1, 2025Research and Development Oncology, Secarna Pharmaceuticals, oncology, research and development
Secarna Pharmaceuticals will present new preclinical data with its lead programme SECN-15 at the American Association for Cancer Research (AACR) …
